A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)
A Phase IIa Study To Investigate The Effects of AER 001 on Antigen Challenge In Atopic Asthmatic Subjects Following Repeated Administration.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Objectives:
Primary Objective
- To investigate the late asthmatic response in mild to moderate asthmatics.. Secondary Objectives
- To examine the effects of AER 001 on cutaneous antigen response, antigen induced airway hyperactivity and sputum eosinophilia.
Methodology: Study Design:
- Single centre, phase IIa, double-blind, randomised, parallel group, repeated dose study in male and female asthmatic subjects.
- A sufficient number of subjects (at least 24 subjects) will be recruited to ensure that at least 20 completed sets of data will be obtained.
- Subjects will be randomised to receive either AER 001 25 mg / Placebo in a ratio of 1 active : 1 placebo.
- Treatments will be administered as a sub-cutaneous injection.
- Subjects are to receive a daily administration of AER 001 / placebo over a 4 week period.
- Subjects will be admitted to the unit at least 2 hours prior to the first dose administration. On the first dosing occasion the subjects will remain in the unit under clinical supervision for at least 30 minutes post dose or until the Investigator is satisfied for them to be discharged. On subsequent dosing days the subjects will be admitted to the unit at least 45 minutes prior to dosing and remain in the unit for at least 15 minutes post dose or until the Investigator is satisfied for them to be discharged.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
London
-
6 Newcomen Street London, London, United Kingdom, SE1 1YR
- Guy's Drug Research Unit, Quintiles, Ltd.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Adult males and females > 18 years.
- Subjects who if female, are not currently pregnant or breast feeding and are using medically acceptable methods of contraception.
- Subjects who have a pre study medical history, physical examination, 12 Lead ECG acceptable to the investigator.
- Subjects who have clinical laboratory tests within the reference ranges or clinically acceptable to the investigator.
- Subjects who are negative for HbsAg, hepatitis C antibody and HIV II and I test at screening.
- Subjects who are negative for drugs of abuse and alcohol tests at screening and admission.
- Positive response on screening to a skin prick test.
- Subjects who respond < 8 mg / mL on the methacholine challenge.
- Subjects, who on the Allergen challenge, have a PC20 on allergen and exhibit a late phase response (>or = 15% between 4-10h) following the allergen challenge.
- Subjects who have a FEV1 >70% of predicted.
- Have not received steroid treatment in the prior month.
- Subjects who are non-smokers for at least 3 months prior to screening.
- Have a < 10 pack year history.
- Satisfies the Global Initiative in Asthma (GINA, 2002) definition of asthma or have been on treatment for asthma.
- Subjects with stable, adequately treated medical conditions may be enrolled provided the Principal Investigator does not consider their study participation to place them at increased risk of adverse events. Subjects should continue their concomitant treatments without change during the study.
- Subjects who are able and willing to give written informed consent.
Exclusion Criteria:
• Subjects who do not conform to the above inclusion criteria.
- Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders. Which would preclude antigen challenge
- Subjects who have a clinically relevant surgical history. Which would preclude antigen challenge
- Subjects who have a clinically relevant family history. Which would preclude antigen challenge
- Subjects who have a history of relevant drug hypersensitivity.
- Subjects who have a history of alcoholism.
- Subjects who have a history of drug abuse.
- Subjects who consume more than 28 units of alcohol a week. (unit = 1 glass of wine = 1 measure of spirits = ½ pint of beer)
- Subjects who have a significant infection or known inflammatory process on screening.
- Subjects who have acute gastrointestinal symptoms at the time of screening and/or admission (e.g. nausea, vomiting, diarrhoea, heartburn)
- Subjects who have an acute infection such as influenza at the time of screening and/or admission.
- Female subjects who are not using an acceptable method of contraception.
- Subjects who have used any investigational drug and /or participated in any clinical trial within 3 months of their first dosing.
- Subjects using medication, which in the opinion of the Investigator will affect the outcome of the study.
- Subjects who have donated and/or received any blood or blood products within the previous 3 months prior to first dosing (to review on a case by case basis).
- Subjects who cannot communicate reliably with the investigator.
- Subjects who are unlikely to co-operate with the requirements of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: A
AER 001 s.c.
once daily for 28 days
|
AER 001 25 mgs s.c.
once daily for 28 days
|
|
Placebo Comparator: P
placebo s.c.
once daily for 28 days
|
sterile saline
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Max %fall in FEV1 during the late phase asthmatic response (4-10 hours after allergen challenge)
Time Frame: After 28 days of treatment with study medication
|
After 28 days of treatment with study medication
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To examine the effects of AER 001 on cutaneous antigen response, antigen induced airway hyperactivity and sputum eosinophilia.
Time Frame: After 28 days of treatment with study medication
|
After 28 days of treatment with study medication
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Darren Wilbraham, M.D., Guy's Drug Research Unit, Quintiles, Ltd.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- QGUY/2004/IL4-13/-01
- EUDRACT 2004-002836-25
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.